Trade Hikma Pharmaceuticals PLC - HIK CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.19 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.025255% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003337% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | GBP | ||||||||
Margin | 5% | ||||||||
Stock exchange | United Kingdom of Great Britain and Northern Ireland | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Hikma Pharmaceuticals PLC ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 20.91 |
Open* | 20.73 |
1-Year Change* | 71.89% |
Day's Range* | 20.56 - 20.94 |
52 wk Range | 11.75-22.22 |
Average Volume (10 days) | 329.07K |
Average Volume (3 months) | 8.27M |
Market Cap | 4.63B |
P/E Ratio | 39.72 |
Shares Outstanding | 221.01M |
Revenue | 2.19B |
EPS | 0.53 |
Dividend (Yield %) | 2.28368 |
Beta | 0.43 |
Next Earnings Date | Feb 21, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Sep 25, 2023 | 20.91 | 0.10 | 0.48% | 20.81 | 21.16 | 20.72 |
Sep 22, 2023 | 20.96 | 0.04 | 0.19% | 20.92 | 21.08 | 20.74 |
Sep 21, 2023 | 21.06 | -0.08 | -0.38% | 21.14 | 21.37 | 20.95 |
Sep 20, 2023 | 21.15 | -0.02 | -0.09% | 21.17 | 21.49 | 20.99 |
Sep 19, 2023 | 20.99 | 0.15 | 0.72% | 20.84 | 21.10 | 20.83 |
Sep 18, 2023 | 20.93 | 0.55 | 2.70% | 20.38 | 20.96 | 20.38 |
Sep 15, 2023 | 20.59 | -0.35 | -1.67% | 20.94 | 21.03 | 20.42 |
Sep 14, 2023 | 20.65 | -0.13 | -0.63% | 20.78 | 20.89 | 20.60 |
Sep 13, 2023 | 20.59 | -0.17 | -0.82% | 20.76 | 20.85 | 20.58 |
Sep 12, 2023 | 20.89 | 0.20 | 0.97% | 20.69 | 21.05 | 20.38 |
Sep 11, 2023 | 20.59 | -0.21 | -1.01% | 20.80 | 21.03 | 20.39 |
Sep 8, 2023 | 20.79 | -0.07 | -0.34% | 20.86 | 21.00 | 20.54 |
Sep 7, 2023 | 20.60 | -0.25 | -1.20% | 20.85 | 20.86 | 20.60 |
Sep 6, 2023 | 20.89 | 0.06 | 0.29% | 20.83 | 21.06 | 20.61 |
Sep 5, 2023 | 21.05 | -0.37 | -1.73% | 21.42 | 21.49 | 21.05 |
Sep 4, 2023 | 21.72 | 0.04 | 0.18% | 21.68 | 21.89 | 21.55 |
Sep 1, 2023 | 21.75 | 0.00 | 0.00% | 21.75 | 21.92 | 21.56 |
Aug 31, 2023 | 21.87 | 0.15 | 0.69% | 21.72 | 22.11 | 21.64 |
Aug 30, 2023 | 21.79 | 0.41 | 1.92% | 21.38 | 21.89 | 21.38 |
Aug 29, 2023 | 21.45 | 0.14 | 0.66% | 21.31 | 21.53 | 21.20 |
Hikma Pharmaceuticals PLC Events
Time (UTC) | Country | Event |
---|---|---|
Thursday, November 2, 2023 | ||
Time (UTC) 07:00 | Country GB
| Event November 2023 Hikma Pharmaceuticals PLC Trading Statement Release November 2023 Hikma Pharmaceuticals PLC Trading Statement ReleaseForecast -Previous - |
Wednesday, February 21, 2024 | ||
Time (UTC) 08:30 | Country GB
| Event Full Year 2023 Hikma Pharmaceuticals PLC Earnings Release Full Year 2023 Hikma Pharmaceuticals PLC Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 2517 | 2553 | 2341 | 2203 | 2076 |
Revenue | 2517 | 2553 | 2341 | 2203 | 2076 |
Cost of Revenue, Total | 1252 | 1252 | 1128 | 1108 | 1004 |
Gross Profit | 1265 | 1301 | 1213 | 1095 | 1072 |
Total Operating Expense | 2208 | 1955 | 1739 | 1669 | 1731 |
Selling/General/Admin. Expenses, Total | 509 | 488 | 464 | 453 | 437 |
Research & Development | 144 | 143 | 137 | 126 | 118 |
Unusual Expense (Income) | 200 | -39 | -76 | -60 | 104 |
Other Operating Expenses, Total | 11 | 38 | 44 | 8 | 68 |
Operating Income | 309 | 598 | 602 | 534 | 345 |
Interest Income (Expense), Net Non-Operating | -65 | -41 | -33 | -27 | -39 |
Other, Net | -11 | -13 | -11 | -16 | -13 |
Net Income Before Taxes | 233 | 544 | 558 | 491 | 293 |
Net Income After Taxes | 191 | 420 | 430 | 487 | 285 |
Minority Interest | -3 | 1 | 1 | -1 | -3 |
Net Income Before Extra. Items | 188 | 421 | 431 | 486 | 282 |
Net Income | 188 | 421 | 431 | 486 | 282 |
Income Available to Common Excl. Extra. Items | 188 | 421 | 431 | 486 | 282 |
Income Available to Common Incl. Extra. Items | 188 | 421 | 431 | 486 | 282 |
Dilution Adjustment | 0 | ||||
Diluted Net Income | 188 | 421 | 431 | 486 | 282 |
Diluted Weighted Average Shares | 225 | 233 | 238 | 243 | 242 |
Diluted EPS Excluding Extraordinary Items | 0.83556 | 1.80687 | 1.81092 | 2 | 1.16529 |
Dividends per Share - Common Stock Primary Issue | 0.55789 | 0.55055 | 0.50649 | 0.4714 | 0.37647 |
Diluted Normalized EPS | 2.03111 | 1.66094 | 1.4958 | 2.16049 | 1.90496 |
Total Extraordinary Items | 0 | ||||
Depreciation / Amortization | 92 | 73 | 42 | 34 |
Jun 2023 | Dec 2022 | Jun 2022 | Dec 2021 | Jun 2021 | |
---|---|---|---|---|---|
Total revenue | 1427 | 1304 | 1213 | 1337 | 1216 |
Revenue | 1427 | 1304 | 1213 | 1337 | 1216 |
Cost of Revenue, Total | 694 | 662 | 590 | 652 | 600 |
Gross Profit | 733 | 642 | 623 | 685 | 616 |
Total Operating Expense | 1184 | 1244 | 964 | 1082 | 873 |
Selling/General/Admin. Expenses, Total | 260 | 253 | 256 | 256 | 232 |
Research & Development | 64 | 75 | 69 | 84 | 59 |
Depreciation / Amortization | 43 | 49 | 43 | 44 | 29 |
Unusual Expense (Income) | 119 | 193 | 7 | 24 | -63 |
Other Operating Expenses, Total | 4 | 12 | -1 | 22 | 16 |
Operating Income | 243 | 60 | 249 | 255 | 343 |
Interest Income (Expense), Net Non-Operating | -41 | -42 | -34 | -30 | -24 |
Net Income Before Taxes | 202 | 18 | 215 | 225 | 319 |
Net Income After Taxes | 131 | 17 | 174 | 172 | 248 |
Minority Interest | 0 | -2 | -1 | 1 | 0 |
Net Income Before Extra. Items | 131 | 15 | 173 | 173 | 248 |
Net Income | 131 | 15 | 173 | 173 | 248 |
Income Available to Common Excl. Extra. Items | 131 | 15 | 173 | 173 | 248 |
Income Available to Common Incl. Extra. Items | 131 | 15 | 173 | 173 | 248 |
Diluted Net Income | 131 | 15 | 173 | 173 | 248 |
Diluted Weighted Average Shares | 222 | 222 | 228 | 234 | 232 |
Diluted EPS Excluding Extraordinary Items | 0.59009 | 0.06757 | 0.75877 | 0.73932 | 1.06897 |
Dividends per Share - Common Stock Primary Issue | 0.25 | 0.35715 | 0.19 | 0.37405 | 0.18 |
Diluted Normalized EPS | 1.14865 | 1.1982 | 0.83772 | 0.90171 | 0.75862 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 1999 | 2094 | 1922 | 1848 | 1668 |
Cash and Short Term Investments | 292 | 450 | 347 | 465 | 276 |
Cash | 159 | 155 | 85 | 94 | 112 |
Cash & Equivalents | 1 | 22 | 35 | 39 | 36 |
Short Term Investments | 132 | 273 | 227 | 332 | 128 |
Total Receivables, Net | 841 | 876 | 734 | 749 | 748 |
Accounts Receivable - Trade, Net | 777 | 781 | 662 | 637 | 654 |
Total Inventory | 776 | 695 | 757 | 568 | 528 |
Prepaid Expenses | 74 | 65 | 58 | 49 | 57 |
Other Current Assets, Total | 16 | 8 | 26 | 17 | 59 |
Total Assets | 4471 | 4372 | 4135 | 3930 | 3497 |
Property/Plant/Equipment, Total - Net | 1081 | 1146 | 1068 | 962 | 870 |
Property/Plant/Equipment, Total - Gross | 2008 | 1955 | 1841 | 1690 | 1549 |
Accumulated Depreciation, Total | -927 | -809 | -773 | -728 | -679 |
Goodwill, Net | 389 | 285 | 289 | 282 | 279 |
Intangibles, Net | 735 | 607 | 587 | 552 | 487 |
Long Term Investments | 52 | 46 | 34 | 29 | 38 |
Other Long Term Assets, Total | 215 | 194 | 235 | 257 | 155 |
Total Current Liabilities | 1077 | 1016 | 1028 | 1471 | 893 |
Accounts Payable | 291 | 262 | 279 | 286 | 263 |
Accrued Expenses | 171 | 194 | 175 | 173 | 185 |
Notes Payable/Short Term Debt | 75 | 64 | 117 | 60 | 65 |
Current Port. of LT Debt/Capital Leases | 73 | 57 | 51 | 518 | 10 |
Other Current Liabilities, Total | 467 | 439 | 406 | 434 | 370 |
Total Liabilities | 2336 | 1919 | 2000 | 1813 | 1812 |
Total Long Term Debt | 1135 | 725 | 764 | 107 | 562 |
Long Term Debt | 1074 | 651 | 692 | 48 | 539 |
Capital Lease Obligations | 61 | 74 | 72 | 59 | 23 |
Deferred Income Tax | 19 | 24 | 31 | 20 | 16 |
Minority Interest | 13 | 14 | 13 | 12 | 12 |
Other Liabilities, Total | 92 | 140 | 164 | 203 | 329 |
Total Equity | 2135 | 2453 | 2135 | 2117 | 1685 |
Common Stock | 40 | 42 | 41 | 41 | 40 |
Additional Paid-In Capital | 282 | 282 | 282 | 282 | 282 |
Retained Earnings (Accumulated Deficit) | 2129 | 2353 | 2011 | 2030 | 1618 |
Treasury Stock - Common | 0 | -1 | -1 | ||
Other Equity, Total | -316 | -224 | -199 | -235 | -254 |
Total Liabilities & Shareholders’ Equity | 4471 | 4372 | 4135 | 3930 | 3497 |
Total Common Shares Outstanding | 220.236 | 231.498 | 230.458 | 242.319 | 241.455 |
Dec 2022 | Jun 2022 | Dec 2021 | Jun 2021 | Dec 2020 | |
---|---|---|---|---|---|
Total Current Assets | 1999 | 2144 | 2094 | 1955 | 1922 |
Cash and Short Term Investments | 292 | 393 | 450 | 346 | 347 |
Cash & Equivalents | 1 | 23 | 22 | 2 | 323 |
Short Term Investments | 132 | 94 | 273 | 101 | 24 |
Total Receivables, Net | 841 | 893 | 811 | 780 | 734 |
Accounts Receivable - Trade, Net | 777 | 784 | 719 | 693 | 662 |
Total Inventory | 776 | 765 | 695 | 736 | 757 |
Prepaid Expenses | 74 | 80 | 65 | 78 | 58 |
Other Current Assets, Total | 16 | 13 | 73 | 15 | 26 |
Total Assets | 4471 | 4747 | 4372 | 4180 | 4135 |
Property/Plant/Equipment, Total - Net | 1081 | 1132 | 1146 | 1061 | 1068 |
Goodwill, Net | 389 | 394 | 285 | 286 | 289 |
Intangibles, Net | 735 | 857 | 607 | 620 | 587 |
Long Term Investments | 52 | 52 | 46 | 36 | 34 |
Other Long Term Assets, Total | 215 | 168 | 194 | 222 | 235 |
Total Current Liabilities | 1077 | 1010 | 1016 | 960 | 1028 |
Accounts Payable | 291 | 255 | 262 | 226 | 279 |
Accrued Expenses | 171 | 160 | 194 | 145 | 175 |
Notes Payable/Short Term Debt | 75 | 76 | 64 | 132 | 117 |
Current Port. of LT Debt/Capital Leases | 73 | 61 | 57 | 49 | 51 |
Other Current Liabilities, Total | 467 | 458 | 439 | 408 | 406 |
Total Liabilities | 2336 | 2571 | 1919 | 1890 | 2000 |
Total Long Term Debt | 1135 | 1414 | 725 | 751 | 764 |
Long Term Debt | 1074 | 1340 | 651 | 676 | 692 |
Capital Lease Obligations | 61 | 74 | 74 | 75 | 72 |
Deferred Income Tax | 19 | 24 | 24 | 21 | 31 |
Minority Interest | 13 | 15 | 14 | 13 | 13 |
Other Liabilities, Total | 92 | 108 | 140 | 145 | 164 |
Total Equity | 2135 | 2176 | 2453 | 2290 | 2135 |
Common Stock | 40 | 41 | 42 | 41 | 41 |
Additional Paid-In Capital | 282 | 282 | 282 | 282 | 282 |
Retained Earnings (Accumulated Deficit) | 2129 | 2143 | 2353 | 2197 | 2011 |
Treasury Stock - Common | 0 | 0 | |||
Other Equity, Total | -316 | -290 | -224 | -230 | -199 |
Total Liabilities & Shareholders’ Equity | 4471 | 4747 | 4372 | 4180 | 4135 |
Total Common Shares Outstanding | 220.236 | 220.113 | 231.498 | 231.432 | 230.458 |
Cash | 159 | 276 | 155 | 243 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 233 | 544 | 558 | 491 | 293 |
Cash From Operating Activities | 530 | 638 | 464 | 472 | 430 |
Cash From Operating Activities | 372 | 145 | 91 | 73 | 69 |
Amortization | 26 | 40 | |||
Non-Cash Items | 112 | 108 | 84 | 34 | 116 |
Cash Taxes Paid | 55 | 129 | 61 | 108 | 63 |
Cash Interest Paid | 68 | 50 | 39 | 44 | 51 |
Changes in Working Capital | -187 | -159 | -269 | -152 | -88 |
Cash From Investing Activities | -607 | -238 | -283 | -151 | -96 |
Capital Expenditures | -225 | -229 | -224 | -186 | -139 |
Other Investing Cash Flow Items, Total | -382 | -9 | -59 | 35 | 43 |
Cash From Financing Activities | -58 | -287 | -298 | -155 | -278 |
Financing Cash Flow Items | -77 | -53 | -34 | -48 | -53 |
Total Cash Dividends Paid | -125 | -120 | -109 | -97 | -84 |
Issuance (Retirement) of Stock, Net | -303 | 0 | -375 | ||
Issuance (Retirement) of Debt, Net | 447 | -114 | 220 | -10 | -141 |
Foreign Exchange Effects | -21 | -10 | -2 | 0 | -7 |
Net Change in Cash | -156 | 103 | -119 | 166 | 49 |
Dec 2022 | Jun 2022 | Dec 2021 | Jun 2021 | Dec 2020 | |
---|---|---|---|---|---|
Net income/Starting Line | 233 | 215 | 544 | 319 | 558 |
Cash From Operating Activities | 530 | 169 | 638 | 224 | 464 |
Cash From Operating Activities | 372 | 95 | 145 | 44 | 91 |
Amortization | |||||
Non-Cash Items | 110 | 48 | 108 | 28 | 84 |
Cash Taxes Paid | 55 | 44 | 129 | 88 | 61 |
Cash Interest Paid | 68 | 27 | 50 | 25 | 39 |
Changes in Working Capital | -185 | -189 | -159 | -167 | -269 |
Cash From Investing Activities | -607 | -506 | -238 | -104 | -283 |
Capital Expenditures | -225 | -119 | -229 | -94 | -224 |
Other Investing Cash Flow Items, Total | -382 | -387 | -9 | -10 | -59 |
Cash From Financing Activities | -58 | 291 | -287 | -112 | -298 |
Financing Cash Flow Items | -77 | -33 | -53 | -26 | -34 |
Total Cash Dividends Paid | -125 | -83 | -120 | -78 | -109 |
Issuance (Retirement) of Debt, Net | 447 | 710 | -114 | -8 | 220 |
Foreign Exchange Effects | -21 | -9 | -10 | -9 | -2 |
Net Change in Cash | -156 | -55 | 103 | -1 | -119 |
Issuance (Retirement) of Stock, Net | -303 | -303 | 0 | 0 | -375 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Darhold Ltd | Corporation | 27.1507 | 60000000 | 0 | 2023-02-22 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 5.2296 | 11556882 | 0 | 2023-02-22 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.5268 | 10003617 | -1477940 | 2023-06-12 | LOW |
Columbia Threadneedle Investments (UK) | Investment Advisor/Hedge Fund | 2.0123 | 4446848 | -117201 | 2023-06-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 1.9841 | 4384669 | -6243 | 2023-06-01 | LOW |
Mawer Investment Management Ltd. | Investment Advisor | 1.7745 | 3921529 | -1080 | 2023-04-30 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.7473 | 3861317 | 0 | 2023-08-01 | LOW |
Schroder Investment Management Ltd. (SIM) | Investment Advisor/Hedge Fund | 1.6069 | 3550974 | -11213 | 2023-08-01 | LOW |
Fidelity International | Investment Advisor | 1.4889 | 3290345 | 0 | 2023-08-01 | LOW |
Polar Capital LLP | Investment Advisor/Hedge Fund | 1.3193 | 2915402 | 997499 | 2023-06-30 | LOW |
Epoch Investment Partners, Inc. | Investment Advisor | 0.9957 | 2200383 | 9231 | 2023-06-01 | LOW |
Aegon Asset Management Ltd | Investment Advisor | 0.9857 | 2178181 | -101093 | 2023-08-01 | LOW |
Baillie Gifford & Co. | Investment Advisor | 0.9057 | 2001573 | 62506 | 2022-12-12 | LOW |
M & G Investment Management Ltd. | Investment Advisor | 0.6445 | 1424294 | -28906 | 2023-08-01 | LOW |
Premier Asset Management Ltd | Investment Advisor/Hedge Fund | 0.6352 | 1403728 | 9290 | 2023-05-31 | LOW |
Darwazeh (Mazen Samih Taleb) | Individual Investor | 0.6116 | 1351507 | 43150 | 2023-04-17 | LOW |
BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 0.5944 | 1313546 | 84436 | 2023-08-01 | LOW |
Al-Husry (Ali) | Individual Investor | 0.5262 | 1162811 | 0 | 2023-02-22 | LOW |
Newton Investment Management Ltd. | Investment Advisor | 0.5211 | 1151544 | -30125 | 2023-06-30 | LOW |
GAM International Management Ltd. | Investment Advisor/Hedge Fund | 0.5023 | 1110079 | 217500 | 2022-12-12 | MED |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Hikma Company profile
Discover the latest Hikma share price today with our comprehensive live chart.
Hikma Pharmaceuticals plc. (HIK) creates and sells generic pharmaceutical solutions and products in the USA, North Africa, Europe, and the Middle East; with its headquarters located in London, UK. The company has operations in more than 50 countries and divides its work into three business units: Branded, Injectables, and Generics.
Hikma owns 29 manufacturing plants in 11 countries: Jordan, Saudi Arabia, Algeria, Egypt, Morocco, Tunisia, Sudan, United States, Portugal, Italy and Germany. The Hikma’s branded division offers 499 products in 1,256 dosage strength. The most popular products are: Amoclan, Omnisef, Blopress and Suprax. The injectables division vendors 200 products in 379 dosage forms.
Hikma pharmaceuticals share price is set and traded on the London Stock Exchange (LSE) under the ticker symbol HIK. The company constitutes the FTSE 100 and FTSE 350 Indices.
Hikma made an initial public offering on 11 November 2005, and Hikma pharmaceuticals shares were listed for the first time, raising gross proceeds of $124 million.
Hikma Pharmaceuticals was founded in Amman, Jordan, by Samih Darwazah in 1978. In August 1996, it became the first Arab company to export pharmaceutical products to the US.
The company’s biggest acquisitions include Jazeera Pharmaceutical, Saudi Arabia; Instituto Biochimico Pavese Pharma, Italy; Baxter International, US; Ribosepharm, Germany; Promopharm, Morocco, and Alkan Pharma, Egypt. All of these strategic acquisitions helped Hikma to establish itself as the world’s leading provider in its industry.
In May 2014, Hikma Pharmaceuticals plc significantly increased its presence in the injected medicine market by purchasing assets from the US generic injectable drugs business of Germany's Boehringer Ingelheim for up to $300 million.
The most recent company acquisition was Roxane Laboratories in Columbus, US. It has majorly improved Hikma's position in a non-injectables business in the US market.
Hikma has been recognised as the Company of the Year by the Global Generics and Biosimilars Awards for four years in a row: from 2014 to 2017.
According to Hikma’s latest earnings report, the company delivered strong growth in revenue and profit in 2019 with a group core revenue of $2,203 million (up 6 per cent) and operating profit of $508 million (up 10 per cent).
Follow the Hikma share price today with Capital.com to spot the best trading opportunities. Track all the ups and downs of the HIK stock price and stay on top of the latest price fluctuations with our live Hikma stock chart.
Industry: | Pharmaceuticals (NEC) |
1 New Burlington Place
LONDON
W1S 2HR
GB
Income Statement
- Annual
- Quarterly
News

USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com